Medtronic PLC $MDT Shares Purchased by Northside Capital Management LLC

Northside Capital Management LLC grew its position in shares of Medtronic PLC (NYSE:MDT) by 412.1% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 110,327 shares of the medical technology company’s stock after acquiring an additional 88,783 shares during the period. Northside Capital Management LLC’s holdings in Medtronic were worth $10,508,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of MDT. Cape Investment Advisory Inc. raised its holdings in Medtronic by 3.2% in the second quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock valued at $314,000 after buying an additional 113 shares during the period. Gilbert & Cook Inc. increased its position in shares of Medtronic by 1.9% in the second quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock worth $532,000 after acquiring an additional 114 shares in the last quarter. Red Spruce Capital LLC raised its stake in shares of Medtronic by 0.5% in the 2nd quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock valued at $2,067,000 after acquiring an additional 118 shares during the period. Certior Financial Group LLC lifted its holdings in shares of Medtronic by 3.7% during the 1st quarter. Certior Financial Group LLC now owns 3,450 shares of the medical technology company’s stock valued at $310,000 after acquiring an additional 122 shares in the last quarter. Finally, Florida Financial Advisors LLC boosted its position in Medtronic by 4.8% during the 2nd quarter. Florida Financial Advisors LLC now owns 2,683 shares of the medical technology company’s stock worth $234,000 after purchasing an additional 122 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on MDT shares. Argus raised their price objective on Medtronic from $105.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, August 26th. JPMorgan Chase & Co. increased their price objective on shares of Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Jefferies Financial Group restated a “hold” rating and issued a $110.00 target price on shares of Medtronic in a research note on Wednesday, November 19th. Sanford C. Bernstein set a $111.00 price target on shares of Medtronic in a research note on Wednesday, November 19th. Finally, The Goldman Sachs Group set a $111.00 target price on Medtronic and gave the company a “neutral” rating in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.11.

Medtronic Price Performance

MDT opened at $97.77 on Wednesday. The company has a market capitalization of $125.34 billion, a P/E ratio of 26.35, a PEG ratio of 2.60 and a beta of 0.71. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $106.33. The company has a 50-day moving average of $97.26 and a 200-day moving average of $93.18. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the firm posted $1.26 earnings per share. Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s payout ratio is currently 76.55%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.